Course: Neoadjuvant Therapy in Recurrent High-Risk Cutaneous Squamous Cell Carcinoma: Advancing Multidisciplinary Decision-Making
CME Credits: 0.25
Released: 2026-09-11
Neoadjuvant immunotherapy is an emerging approach in cutaneous squamous cell carcinoma (cSCC) that may offer meaningful pathologic responses while introducing new questions about treatment sequencing and the need for subsequent therapy. This online, on-demand CME/CE activity—part of the six-part series Mock Tumor Board: Advancing Multidisciplinary Decision-Making in Cutaneous Squamous Cell Carcinoma—presents an interactive mock tumor board case of a patient with recurrent, high-risk cSCC involving a large cervical lymph node. Throughout the discussion, expert faculty examine multidisciplinary decision-making around neoadjuvant immunotherapy and surgery, including factors that may influence the number of neoadjuvant treatment cycles and expectations for treatment response. They also discuss the role of pathologic response in guiding postoperative management, the potential for surveillance following a complete pathologic response, and ongoing questions regarding the optimal sequencing and duration of perioperative immunotherapy. The content for this enduring activity was recorded on August 10, 2026.
Upon completion of this activity, participants should be better able to:
View Full Course